

AREV LIFE SCIENCES GLOBAL CORP.  
PRESS RELEASE

**AREV ADDS DR. APTE TO THE SAB**

VANCOUVER, BC / August 17, 2022 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation AREV Life Sciences Global Corporation announces the appointment of Sateesh Apte MD to the Scientific Advisory Board (the “SAB”) of AREV.

AREV Life Sciences announced the appointment of Sateesh Apte MD to its Scientific Advisory Board, as part of the current scale up for launching clinical studies of SUSTAINN™ for treating Serious Acute Malnutrition in Low & Middle Income Countries. “LMIC”

Dr Apte’s expertise in neurological pathogenesis will complement AREV’s focus on positioning SUSTAINN™ to address the cognitive preservation of children experiencing serious acute malnutrition, which causes brain damage in millions of malnourished children a year. Said Mike Withrow, CEO of AREV Life Sciences Dr. Apte’s appointment to the SAB of AREV is a critical step in successfully designing our studies to demonstrate the clinical value of SUSTAINN in treating SAM.

Dr. Apte specializes in neurology and has an extensive background in research, teaching and consulting in the field of neurological sciences. Dr. Apte’s graduate training was at Haffkine Institute in Mumbai, India, The Pasteur Institute in Paris, France, at Harvard Medical School in Boston and at Stanford University in California. His professional appointments have included active staff positions at the VA Medical Center and Valley Memorial Hospital in Livermore, CA; ValleyCare Medical Center in Pleasanton, CA, and directorships with PainCare Medical Clinic, and the Sleep Disorders Center in San Ramon and Pleasanton, CA. He most recently served as President and CEO of Northern California Physicians Associates, Inc. and Alpha Medical Group, Inc. (1986-1992) He served as President and CEO of ImmunoScience, Inc. in Pleasanton, CA until 2019. Dr. Apte has authored and co-authored a number of articles for medical journals and has several publications pending.

Dr Apte stated “I am very excited to join the AREV SAB as the company commences some of the most important studies in public health for millions of children affected by SAM. The research to attribute the therapeutic effect of SUSTAINN™ promises to be a groundbreaking advance in addressing this leading cause of pediatric mortality during a global famine, that is exacerbating the burden of infectious diseases in developing nations, which has serious implications for global public health and security”.

Dr Apte’s appointment directly follows a series of meetings at AIDS 2022 with AREV’s corporate leadership, involving representatives of UNAIDS, the World Food Program, USAID, The WHO, NIAID, The MHRP, The Global Fund for AIDS, TB and Malaria, PEPFAR to review concept sheet development of initial studies of SUSTAINN being planned for the 1<sup>st</sup> Q of 2023.

Further, the Company is pleased to announce that the Company has issued 100,000 stock options to Directors, Officers and Consultants of the Company at a price of \$0.12 for a period of 5 years from the issuance dated. These options will vest immediately.

**About SUSTAINN™**

Being developed in collaboration with the Richardson Center for FOOD TECHNOLOGIES AND RESEARCH and leadership at OSU’s Linus Pauling Institute. SUSTAINN™ is a next generation Ready to Use Therapeutic Food designed to provide superior clinical value for patients presenting SAM. SUSTAINN™ is intended to address the dysbiosis, enteropathy and loss of intestinal microbiome which characterizes SAM and the long term cognitive degeneration of SAM patients.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit [www.arevlifesciences.com](http://www.arevlifesciences.com).

On behalf of the Board,

Mike Withrow  
CEO & Director

### **About AREV Life Sciences Global Corp.**

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECANADA and The Biotechnology Innovation Organization (BIO).

**NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**

### **FORWARD LOOKING INFORMATION**

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com).